Figure 11Àº Scan-to-Scan AGC(automatic gain control) ¸ðµå¿¡¼­ Spectrum MultiplexingÀ» ºñ±³ÇÑ °ÍÀÌ´Ù. ¾Æ·¡ A¿Í B¿Í °°ÀÌ ¾çÂÊ ¸ðµå¿¡¼­, Àåºñ´Â Parallel Mode·Î ÀÛµ¿ÇÑ´Ù. Çѹø ½ºÄµÀÌ ÁøÇàµÇ°í µ¥ÀÌÅÍ°¡ ȹµæµÇ´Â µ¿¾È, ´ÙÀ½ ½ºÄµÀ» À§ÇØ À̿µéÀÌ ¹Ì¸® Æ÷ÁýµÈ´Ù. Standard Operation ¸ðµåÀÇ °æ¿ì, ¿ÀÁ÷ ÇϳªÀÇ Precursor ÀÌ¿ÂÀÌ ÁÖÀÔµÇÁö¸¸ ¹Ý¸é, Spectrum Multiplexing ¸ðµå¿¡¼­´Â ³²´Â ½Ã°£¿¡ ´Ù¾çÇÑ Precursor À̿µéÀÌ ÁÖÀԵǾî, º¸´Ù ¸¹Àº °á°ú(Higher Throughput)¸¦ ¾òÀ» ¼ö Àִµ¥ »ç¿ëµÈ´Ù.


Figure 11. Standard operation mode (A)
versus spectrum multiplexing (B).

»õ·Ó°Ô Ãâ½ÃµÈ °í¼º´É Benchtop Quadrupole - Orbitrap MSÀÎ Q ExactiveTM´Â ±âÁ¸ÀÇ °í»ç¾ç Triple Quadrupole MS º¸´Ù ÈξÀ ³·Àº LOQ ¸¦ º¸¿´À¸¸ç, ÀÌ·Î ÀÎÇØ ÇöÁ¸ÇÏ´Â Áú·®ºÐ¼®±â Áß¿¡ °¡Àå ÁÁÀº °¨µµÀÇ Á¤·®ºÐ¼® °á°ú¸¦ µµÃâÇÏ´Â Áú·®ºÐ¼®±â ÀÓÀÌ Áõ¸íµÇ¾ú´Ù.
  Insulin to an LOQ of 250 pg.mL-1
  Exendin-4 to an LOQ of 5 ng.mL-1
  GLP-1 to an LOQ of 0.1 ng.mL-1
Q ExactiveTMÀÇ ´ÙÁß ¼±ÅÃÀ̿ºм®¹ýÀº Insulin, Exendin-4 ±×¸®°í GLP-1¿Í °°Àº Large PeptideÀÇ Á¤·®ºÐ¼®¿¡ ÀÖ¾î ¶Ù¾î³­ °¨µµ¿Í ÀçÇö¼º ÀÖ´Â °á°ú¸¦ ¾òÀ» ¼ö Àֱ⿡ ¸Å¿ì È¿°úÀûÀÌ´Ù.
Q ExactiveTMÀÇ Spectrum Multiplexing ±â´ÉÀº Á¤·®ÇÏ°íÀÚ ÇÏ´Â ºÐ¼®¹°Áú¿¡ ´ëÇÑ ³ôÀº ¼±ÅüºÀ» °¡Áø´Ù. ÀÌ´Â »ç¿ëÇϱâ Æí¸®ÇÑ ´Ù¸¥ ÀÀ¿ë ¼ÒÇÁÆ®¿þ¾î¿Í ÇÔ²² ¼Õ ½±°Ô µ¥ÀÌÅ͸¦ ó¸®ÇÒ ¼ö ÀÖ°í ¾Æ¿ï·¯, UHPLC¿Í °°Àº °í¼º´É LC·Î ¸Å¿ì ªÀº ½Ã°£ µ¿¾È ºÐ¸®µÇ¾î ³ª¿À´Â Peak¿¡ ´ëÇؼ­µµ ÃæºÐÈ÷ ºÐ¼®ÇÒ ¼ö ÀÖÀ» ¸¸Å­ Scan Speed°¡ ºü¸£´Ù. ÀÌ·¯ÇÑ ½ÇÇè °á°ú´Â Peptide¿Í Small Proteins ±×¸®°í Oligonucleotides µîÀÇ Á¤·®ºÐ¼®¿¡ ¸Å¿ì Ź¿ùÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù.